stoxline Quote Chart Rank Option Currency Glossary
BioDelivery Sciences International, Inc. (BDSI)
5.59  -0.005 (-0.09%)    03-22 16:00
Open: 5.6
High: 5.6
Volume: 2,107,479
Pre. Close: 5.595
Low: 5.59
Market Cap: 577(M)
Technical analysis
2022-11-18 4:18:56 PM
Short term     
Mid term     
Targets 6-month :  6.53 1-year :  6.54
Resists First :  5.59 Second :  5.59
Pivot price 5.59
Supports First :  5.59 Second :  4.65
MAs MA(5) :  5.59 MA(20) :  5.59
MA(100) :  5.59 MA(250) :  5.05
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  0 D(3) :  0
RSI RSI(14): 83.1
52-week High :  5.61 Low :  2.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BDSI ] has closed Bollinger Bands are 0% narrower than normal.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.61 - 5.63 5.63 - 5.66
Low: 5.52 - 5.56 5.56 - 5.58
Close: 5.54 - 5.59 5.59 - 5.63
Company Description

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Headline News

Mon, 15 Apr 2024
Is the Options Market Predicting a Spike in BioDelivery (BDSI) Stock? - Yahoo New Zealand News

Sun, 14 Apr 2024
What Makes BioDelivery Sciences International (BDSI) a Strong Momentum Stock: Buy Now? - Yahoo Canada Shine On

Tue, 22 Mar 2022
Collegium Completes the Acquisition of BDSI - GlobeNewswire

Sat, 19 Feb 2022
Collegium Pharmaceutical to purchase BioDelivery Sciences for $604m - Pharmaceutical Technology

Tue, 15 Feb 2022
Troutman Pepper Counsels Collegium Pharmaceutical in Pending $604M Acquisition of BioDelivery Sciences ... - Troutman Pepper

Mon, 14 Feb 2022
Collegium Purchases BioDelivery Sciences International in All-Cash Deal - Contract Pharma

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 99 (M)
Shares Float 87 (M)
Held by Insiders 2.7 (%)
Held by Institutions 68.8 (%)
Shares Short 2,010 (K)
Shares Short P.Month 1,690 (K)
Stock Financials
EPS 0.23
EPS Est Next Qtrly -0.22
EPS Est This Year 0.11
EPS Est Next Year -0.64
Book Value (p.s.) 1.07
Profit Margin 18.8 %
Operating Margin 24.3 %
Return on Assets (ttm) 10.4 %
Return on Equity (ttm) 28.5 %
Qtrly Rev. Growth 4.1 %
Gross Profit (p.s.) 1.33
Sales Per Share 1.67
EBITDA (p.s.) 0.47
Qtrly Earnings Growth -24.9 %
Operating Cash Flow 38 (M)
Levered Free Cash Flow 36 (M)
Stock Valuations
PE Ratio 23.29
PEG Ratio 0
Price to Book value 5.22
Price to Sales 3.33
Price to Cash Flow 14.42
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android